| 000 | 01898 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516042916.0 | ||
| 264 | 0 | _c20120402 | |
| 008 | 201204s 0 0 eng d | ||
| 022 | _a1873-4294 | ||
| 024 | 7 |
_a10.2174/156802611797633410 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMahadeswaraswamy, Y H | |
| 245 | 0 | 0 |
_aDaboia russelli venom hyaluronidase: purification, characterization and inhibition by β-3-(3-hydroxy-4-oxopyridyl) α-amino-propionic Acid. _h[electronic resource] |
| 260 |
_bCurrent topics in medicinal chemistry _c2011 |
||
| 300 |
_a2556-65 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntivenins _xchemistry |
| 650 | 0 | 4 | _aCircular Dichroism |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aElectrophoresis, Polyacrylamide Gel |
| 650 | 0 | 4 |
_aGroup II Phospholipases A2 _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aHemorrhage _xdrug therapy |
| 650 | 0 | 4 |
_aHyaluronoglucosaminidase _xantagonists & inhibitors |
| 650 | 0 | 4 | _aHydrogen-Ion Concentration |
| 650 | 0 | 4 | _aInhibitory Concentration 50 |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 |
_aMimosine _xchemistry |
| 650 | 0 | 4 | _aMolecular Weight |
| 650 | 0 | 4 |
_aMuscles _xdrug effects |
| 650 | 0 | 4 | _aProtein Binding |
| 650 | 0 | 4 | _aProtein Conformation |
| 650 | 0 | 4 |
_aDaboia _xphysiology |
| 650 | 0 | 4 | _aSnake Bites |
| 650 | 0 | 4 | _aSpectrometry, Fluorescence |
| 650 | 0 | 4 | _aSpectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization |
| 650 | 0 | 4 | _aSubstrate Specificity |
| 650 | 0 | 4 |
_aViper Venoms _xantagonists & inhibitors |
| 700 | 1 | _aManjula, B | |
| 700 | 1 | _aDevaraja, S | |
| 700 | 1 | _aGirish, K S | |
| 700 | 1 | _aKemparaju, K | |
| 773 | 0 |
_tCurrent topics in medicinal chemistry _gvol. 11 _gno. 20 _gp. 2556-65 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2174/156802611797633410 _zAvailable from publisher's website |
| 999 |
_c20937200 _d20937200 |
||